Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

“…More importantly, these conjugate NPs resulted in an improved therapeutic outcome compared to each treatment moiety alone [143]. Similar observations could be made when paclitaxel was co-encapsulated with SP-LPS into PLGA NPs [144].…”

Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer

“…The efficacy of the current system exceeded that of previously reported PLGA nanoparticles containing PTX tested on mammary adenocarcinoma and melanoma. 47,48 The clinical advantage of the current delivery system is even more definitive when compared with previously reported cell membrane-based nanoparticles or nanocapsules. 24,43,49 The use of local LDI as a new chemoattractant and sensitizer for drug …”

Multifunctional nanoparticles for cancer immunotherapy

“…In this study paclitaxel as a cytotoxic drug was co-encapsulated with a TLR4 agonist through a PLGA based nanoparticle and evaluated its anticancer activity. 85 The mean diameter of the particles was found to be 255 nm. In vivo tumor regression studies demonstrated that when paclitaxel was co-encapsulated with TLR4 agonist into PLGA NPs resulted in an improved therapeutic outcome compared to the paclitaxel alone.…”

“…The mean tumor volume of the NPs treated animals was found to be 40% less than that of the Paclitaxel treated animals. 85 Indeed, in the tumor microenvironment TLR4 agonist converts TAMs into M1 macrophages. On the other hand, in a synergistic manner, apoptotic bodies produced by cytotoxic activity of paclitaxel giving the immune system new targets to combat, resulting in more activation of antigen presenting cells and T cytotoxic cells.…”